Neurodegeneration

Amyloid-β and tau biomarkers and clinical phenotype in dementia with Lewy bodies

- Dr. Kejal Kantarci

Cerebrovascular and tau pathologies contribute to gray matter neurodegeneration in dementia with Lewy bodies.

- Dr. Daniel Ferreira Padilla

Selecting software pipelines for change in flortaucipir SUVR.

- Dr. Christopher Schwarz

Alzheimer’s disease continuum profiled by fluid and imaging biomarkers within the ATN framework

- Dr. Marco Bucci

What could tau PET tell us about the course of Alzheimer’s disease?

- Dr. Konstantinos Ioannou

Discussion - all speakers (30 minutes)

Imaging biomarkers beyond Aβ and Tau 1,

- Dr. Amit Kumar

Reactive Astrocytes Imaged with 11C-Deuterium-L-Deprenyl PET in Alzheimer's Disease.

- Ms. Malgorzata Michalowska

Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer’s pathophysiology

- Dr. Vijay Ramanan

Mapping and understanding Tau pathology in FTD subtypes and AD using the tau PET tracer PI2620.

- Ms. Mona-Lisa Malarte

Pattern of brain glucose metabolism in isolated rapid eye movement sleep behavior disorder (iRBD) and its association with dopamine transporter availability.

- Dr. Patricia Diaz-Galvan

Neurodegeneration-based subtypes of Alzheimer's disease: a multimodal perspective from FDG-PET and MRI biomarkers.

- Ms. Sophia Wheatley

Discussion - all speakers (30 minutes)

Future use and implementation of AD blood biomarkers from a clinical and epidemiological perspective

- Dr. Michelle Mielke

Factors underlying discordance in amyloid PET vs CSF: Validation of a continuous model of biomarker discordance across cohorts and PET tracers.

- Dr. Elena Rodriguez-Vieitez

Relationship between synaptic, axonal, tau and astrocytic biomarkers with brain imaging and cognition over the course of Alzheimer's disease.

- Dr. Joana Pereira

Plasma neurofilament light predicts mortality in patients with stroke.

- Dr. Tania Gendron

Perivascular fibroblasts activity precedes the onset of ALS neurodegeneration.

- Dr. Sebastian Lewandowski

Discussion - all speakers (30 minutes)

In vivo binding of THK5317 and comparability with postmortem 3H-THK5117, 3H-MK6240 autoradiography and AT8 immunostaining in a 4R tauopathy case.

- Dr. Laetitia Lemoine

Neurofibrillary tangle maturity characterization of four phosphorylated tau fluid biomarkers.

- Dr. Christina Moloney

Multimodal assessment of heterogeneity in Alzheimer's disease continuum.

- Dr. Rosaleena Mohanty

Correlates of Neuroimaging measures with Pathological Scales of Cerebrovascular Disease

- Dr. Aivi Nguyen

In vivo model of the cholineric pathways in aging and Alzheimer's disease.

- Mr. Milan Nemy

Mayo Test Drive: Reliability and construct validity of the Stricker Learning Span and Symbols Test on a self-administered web-based testing platform optimized for smartphone

- Dr. Aimee Karstens

Discussion - all speakers (30 minutes)